middle.news
CLINUVEL’s MD Returns Full-Time, Steering Key Projects Amid Leadership Transition
9:46am on Friday 13th of June, 2025 AEST
•
Pharmaceuticals
Read Story
CLINUVEL’s MD Returns Full-Time, Steering Key Projects Amid Leadership Transition
9:46am on Friday 13th of June, 2025 AEST
Key Points
Dr Philippe Wolgen resumes full-time Managing Director role
Focus on advancing specific product development and corporate projects
Lachlan Hay remains Acting CEO until end of September 2025
Strategic leadership alignment for next critical phase
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CLINUVEL PHARMACEUTICALS (ASX:CUV)
OPEN ARTICLE